Last year, pharmaceutical giant AstraZeneca embarked on an ambitious program to use next-generation genome sequencing to develop drugs to fight all kinds of disease, including cancer.
The technology creates a synthetic version of messenger RNA, which helps create protein in cells. If successful, the proteins could fight cancer, among other diseases.
Unfortunately, such genomic sequencing requires a great deal of computing power. As Jason Tetrault, architect of R&D information at AstraZenaca explained recently, analyzing 88 whole human genomes took 15,000 hours and 171 terabytes (TB) of data. Analyzing a single human genome can take four days.
Fortunately, breakthroughs in genetics... Read More >